It is estimated that 80 percent of women have some degree of cellulite. Although there are no permanent solutions for cellulite, dermatologists recognize that this is an issue of importance for many women. This guide reviews current research on the pathophysiology and treatment of cellulite, as well as the many recent developments in medical therapy, liposculpture, and pharmacy to combat the appearance of cellulite in the female figure. Подсчитано, что 80 процентов женщин имеют некоторую степень целлюлита. Хотя нет постоянного решения для целлюлита, дерматологи признать, что это важный вопрос для многих женщин. Это руководство рассматривает текущее исследование по патофизиологии и лечения целлюлита, а также многие последние события в медицинской терапии, липоскульптура, и фармации по борьбе появление целлюлита в женской фигуры.
Author(s): Mitchel P. Goldman, Gustavo Leibaschoff, Doris Hexsel, Pier Antonio Bacci
Series: Basic and Clinical Dermatology
Edition: 1
Publisher: Informa Healthcare
Year: 2006
Language: English
Pages: 353
Cover Page......Page 1
BASIC AND CLINICAL DERMATOLOGY......Page 3
Title Page......Page 6
ISBN 0824729854......Page 7
Series Introduction......Page 8
Foreword......Page 10
Preface......Page 12
WHY CELLULITE IS A CONCERN FOR US......Page 14
REFERENCES......Page 16
Contents......Page 18
Contributors......Page 24
INTRODUCTION......Page 26
ASPECTS OF CELLULITE RELATED TO QOL......Page 27
CONCLUSIONS......Page 29
REFERENCES......Page 30
DEFINITION......Page 32
CLINICAL ASPECTS......Page 34
CLINICAL APPROACH......Page 36
AGGRAVATING FACTORS......Page 41
COMPLEMENTARY EXAMINATIONS......Page 44
DIFFERENTIAL DIAGNOSIS......Page 46
REFERENCES......Page 49
APPENDIX......Page 52
CELLULITE......Page 54
LYMPHEDEMA......Page 55
DERCUM SYNDROME......Page 56
INTERSTITIAL MATRIX......Page 57
REFERENCES......Page 63
DEFINITION......Page 66
CLASSIFICATION......Page 68
WHAT IS THE RELATIONSHIP BETWEEN CELLULITE AND OBESITY?......Page 72
PREDISPOSING FACTORS......Page 73
TRIGGERING FACTORS......Page 74
LIPEDEMA AND LIPOLYMPHEDEMA: PATHOLOPHYSIOLOGIC HYPOTHESES......Page 75
LYMPH......Page 77
LYMPHATIC CIRCULATION......Page 78
THE FIBROBLAST AND THE INTERSTITIAL MATRIX......Page 79
THE ADIPOCYTE......Page 80
HYPODERMIS AND FAT METABOLISM......Page 81
LIPODYSTROPHY......Page 82
THE LYMPHOADIPOSE SYSTEM......Page 83
VENOUS–LYMPHATIC STASIS......Page 86
MANIFESTATIONS OF CELLULITE......Page 87
LIPOSCLEROSIS AND LOCALIZED ADIPOSITY......Page 88
ABOUT GLYCOSAMINOGLYCANS......Page 92
ETIOPATHOGENIC FACTORS......Page 93
THE TERM ‘‘CELLULITE’’......Page 95
REFERENCES......Page 97
CLINICAL EXAMINATION......Page 100
PALPATION......Page 103
ADIPOSE TISSUE ECHOGRAPHY......Page 104
LABORATORY INVESTIGATIONS......Page 105
ROM TEST......Page 106
VIDEOCAPILLAROSCOPY......Page 107
ECHOGRAPHY/ULTRASOUND......Page 109
DOPPLER......Page 111
ECHODOPPLER......Page 112
DIAGNOSIS......Page 113
Generalized Cellulite......Page 114
Localized Cellulite......Page 115
Hard Cellulite......Page 116
Soft Cellulite......Page 117
Edematous Cellulite......Page 118
EVOLUTION......Page 119
MEDICAL HISTORY......Page 120
REFERENCES......Page 122
APPENDIX......Page 123
SUBJECTS......Page 130
MR IMAGING......Page 131
STATISTICS......Page 132
ADIPOSE THICKNESS......Page 133
3-D ARCHITECTURE OF ADIPOSE TISSUE......Page 134
DISCUSSION......Page 137
REFERENCES......Page 139
BINAZZI’S CLASSIFICATION......Page 140
BARTOLETTI’S CLASSIFICATION......Page 141
BIMED CLASSIFICATION......Page 142
THE C FACTOR......Page 152
TCD CODE......Page 154
PATHOPHYSIOLOGICAL CLASSIFICATION AND PROTOCOLS OF BIMED–TCD......Page 155
EDEMATOUS CELLULITE......Page 156
THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days)......Page 158
ADIPOSE CELLULITE......Page 159
INTERSTITIAL CELLULITE (LIPEDEMA)......Page 160
THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days)......Page 161
FIBROUS CELLULITE......Page 162
THERAPEUTIC PROTOCOL (60 DAYS) Phase 1 (20 Days)......Page 163
SUMMARY......Page 164
REFERENCES......Page 165
INTRODUCTION......Page 168
MELILLOTUS OFFICINALIS EXTRACT......Page 169
FUCUS VESCICULOSUS EXTRACT......Page 170
ABSTRACTS OF STUDIES IN CELLASENE......Page 171
NEW RESEARCH ABOUT THE USE OF CELLASENE OR CELLULASE GOLD......Page 172
REFERENCES......Page 178
9 Theory and Working Principles of Beautytek1 in Cosmetic Medicine......Page 180
INTRODUCTION......Page 184
PATHOPHYSIOLOGIC MECHANISMS OF CELLULITE FORMATION......Page 185
TOPICAL MANAGEMENT......Page 186
AGENTS THAT INCREASE MICROVASCULAR FLOW......Page 187
AGENTS THAT REDUCE LIPOGENESIS AND PROMOTE LIPOLYSIS......Page 189
AGENTS THAT PREVENT OR DESTROY FREE-RADICAL FORMATION......Page 190
EXTERNAL AIDS TO TOPICAL THERAPY......Page 191
CONCLUSION......Page 193
REFERENCES......Page 194
INTRODUCTION......Page 196
DERMIS......Page 198
The Connective Tissue......Page 199
ADIPOSE TISSUE AND LIPODERMA......Page 201
THE SUPERFICIAL FASCIA......Page 202
What Is Endermologie–Cellu M6?......Page 203
MECHANISM OF ACTION......Page 204
CELLULITIC SYNDROMES Cellulite and Endermologie......Page 206
METHOD......Page 207
CONCLUSIONS......Page 210
REFERENCES......Page 211
PARAMETERS......Page 214
INITIAL STUDIES......Page 215
PROTOCOL......Page 216
INTRODUCTION......Page 222
INDICATIONS......Page 223
TREATMENT METHOD......Page 226
CONTRAINDICATIONS......Page 228
PROTOCOL FOR CARBOXYTHERAPY IN CELLULITE......Page 230
CONCLUSIONS......Page 232
REFERENCES......Page 234
LIPOPLASTY......Page 236
HISTORICAL BACKGROUND......Page 237
B: VASER......Page 245
DEFINITION......Page 247
PATIENT SELECTION......Page 248
PRESURGICAL VISIT......Page 249
DETAILED PHYSICAL EXAMINATION......Page 252
PRESCRIPTIONS......Page 253
POSTOPERATIVE SCHEME &......Page 254
CONCLUSION......Page 255
INTRODUCTION......Page 256
THE VIBRO-ASSISTED METHOD......Page 257
D: Lipofilling......Page 259
LIFTING......Page 261
LIPOSHIFTING......Page 262
E: Ultrasonic Hydrolipoclasis (External Ultrasound)......Page 264
BIOLOGICAL EFFECTS......Page 267
INFILTRATION......Page 269
ULTRASOUND APPLICATION......Page 270
SIDE EFFECTS......Page 271
REFERENCES......Page 273
INDICATIONS AND MECHANISMS OF ACTION......Page 276
SURGICAL TECHNIQUE......Page 279
COMPLICATIONS......Page 282
CONCLUSIONS......Page 285
REFERENCES......Page 287
THE CONCEPT......Page 288
BICHERON’S MICROCIRCULATORY THEORY......Page 289
BENEFITS AND ADVANTAGES OF THE METHOD......Page 290
MANUAL TECHNIQUES......Page 291
SIDE EFFECTS......Page 292
COMPLICATIONS (8–45)......Page 294
FACE AND NECK REJUVENATION WITH MESOLIFT......Page 295
WHAT DRUGS ARE USED?......Page 296
SUBSTANCE USED......Page 297
PROCEDURE......Page 299
MATERIALS REQUIRED (19)......Page 300
CONJOCTYL (SALICYLATE OF MONOMETILSILANOTRIOL) (24)......Page 302
MELILOTUS-RUTOSIDO (26)......Page 303
CAFFEINE......Page 304
THEOPHYLLINE......Page 305
YOHIMBINE......Page 306
NO-NEEDLE MESOTHERAPY......Page 307
DIFFERENCES BETWEEN THE RESULTS OF MESOTHERAPY AND LIPOSCULPTURE......Page 308
REFERENCES......Page 309
17 Manual Lymphatic Drainage......Page 312
REFERENCES......Page 315
INTRODUCTION......Page 316
CHARACTERISTIC FEATURES......Page 317
DERMOELECTROPORATION TREATMENT......Page 318
CLINICAL STUDY......Page 319
ACKNOWLEDGMENT......Page 322
REFERENCES......Page 323
INTRODUCTION......Page 326
PHOSPHATIDYLCHOLINE (PC)......Page 327
DEOXYCHOLATE (DEOXYCHOLIC ACID)......Page 330
LIPOSTABIL1 IN THE UNITED STATES AND CANADA......Page 331
SYSTEMIC SIDE EFFECTS (CHOLINERGIC)......Page 332
GENERAL CONSIDERATIONS FOR LIPODISSOLVE INJECTIONS......Page 334
LIPODISSOLVE FORMULAE FOR FAT PAD DISSOLUTION......Page 335
LIDOCAINE......Page 336
TYPICAL INJECTION PATTERN USING A 5ML SYRINGE (FIG. 3)......Page 337
LIPODISSOLVE SUMMARY: SIMPLE INJECTIONS FOR FAT REDUCTION......Page 338
REFERENCES......Page 347
Index......Page 348
